BUSINESS Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONICTM Phase 2 Trial of LP-300 in Never-Smokers with NSCLC Tuesday, May 19, 2026 Advertisement Read Original Article → Related Dispatches [US] · Jun 4 U.S. House committee rejects Moore’s funding proposal for drinking water in Southern West Virginia [US] · Jun 4 NuScale Power Stock Is Down 20%. Is It Finally Time to Buy? [US] · May 30 The Chip That Lifted a Nation – and What It Means for Your Portfolio